Literature DB >> 16257792

Fever of unknown origin and cancer: a population-based study.

Henrik Toft Sørensen1, Lene Mellemkjaer, Mette Vinther Skriver, Søren P Johnsen, Bente Nørgård, Jørgen H Olsen, John A Baron.   

Abstract

BACKGROUND: Fever of unknown origin is associated with cancer, but the tumour types most commonly involved and the prognostic implications of this relation have not been studied. We aimed to assess the risk of cancer and survival after hospital admission for fever of unknown origin in a nationwide Danish follow-up study.
METHODS: We linked the Danish national registry of patients and the nationwide cancer registry, and assessed cancer risk for 43,205 patients discharged for the first time from Danish hospitals after admission for fever of unknown origin during 1977-97. We compared cancer frequency with that expected on the basis of cancer incidence in the general population, and survival of patients with cancer who had had fever of unknown origin with that of controls (ie, patients with cancer matched for cancer site, age at time of cancer diagnosis, and year of cancer diagnosis).
FINDINGS: Median follow-up was 6.3 years (IQR 2.7-12.3). During the first year of follow-up, 399 cancers were diagnosed in those who had had fever of unknown origin (standardised incidence ratio 2.3 [95% CI 2.1-2.5]). These individuals had an increased risk of developing cancer--in particular haematological malignant disease; sarcoma; and cancers of the liver, brain, kidney, colon, and pancreas. After 1 year of follow-up, individuals had an increased risk of developing haematological malignant disease and cancers of the liver, brain, and kidney. A slightly higher proportion of people diagnosed with cancer within 1 year of hospital discharge after fever of unknown origin had distant metastases compared with controls (101 [34%] of 294 vs 819 [28%] of 2907; prevalence ratio 1.2 [95% CI 1.0-1.4], and had worse survival than did controls (mortality rate ratio 1.4 [95% CI 1.2-1.6]).
INTERPRETATION: Hospital admission for fever of unknown origin is a marker of occult cancer and is associated with a poor outlook.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257792     DOI: 10.1016/S1470-2045(05)70346-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  6 in total

1.  Hepatitis C virus infection and risk of cancer: a population-based cohort study.

Authors:  Lars Haukali Omland; Dora Körmendiné Farkas; Peter Jepsen; Niels Obel; Lars Pedersen
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

2.  Carcinoma of Colon: a rare cause of fever of unknown origin.

Authors:  Wei Dai; Kyu-Sung Chung
Journal:  Chin J Cancer Res       Date:  2012-06       Impact factor: 5.087

3.  Cost-benefit analysis of introducing next-generation sequencing (metagenomic) pathogen testing in the setting of pyrexia of unknown origin.

Authors:  Jia Hui Chai; Chun Kiat Lee; Hong Kai Lee; Nicholas Wong; Kahwee Teo; Chuen Seng Tan; Praveen Thokala; Julian Wei-Tze Tang; Paul Anantharajah Tambyah; Vernon Min Sen Oh; Tze Ping Loh; Joanne Yoong
Journal:  PLoS One       Date:  2018-04-17       Impact factor: 3.240

4.  Undifferentiated Pleomorphic Sarcoma with Neoplastic Fever: A Retrospective Study.

Authors:  Jiaqiang Wang; Shuping Dong; Jianpo Zhang; Shilei Gao; Zhehuang Li; Po Li; Junhui Yuan; Zhichao Tian
Journal:  Cancer Manag Res       Date:  2021-11-10       Impact factor: 3.989

5.  A Rare Case of Undifferentiated Pleomorphic Cardiac Sarcoma with Inflammatory Pattern.

Authors:  Alexandra Iulia Stoica; Marius Mihai Harpa; Cosmin Marian Banceu; Claudiu Ghiragosian; Carmen Elena Opris; Hussam Al-Hussein; Hamida Al-Hussein; Sanziana Flamind Oltean; Tibor Mezei; Razvan Gheorghita Mares; Horatiu Suciu
Journal:  Medicina (Kaunas)       Date:  2022-07-28       Impact factor: 2.948

6.  Elevated plasma vitamin B12 levels as a marker for cancer: a population-based cohort study.

Authors:  Johan Frederik Berg Arendt; Lars Pedersen; Ebba Nexo; Henrik Toft Sørensen
Journal:  J Natl Cancer Inst       Date:  2013-11-18       Impact factor: 13.506

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.